TYAN
22.6.2020 17:02:12 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its latest lineup of HPC, storage, cloud and embedded platforms powered by 2nd Gen AMD EPYC™ 7002 series processors and 2nd Gen Intel® Xeon® Scalable Processors at TYAN server solutions online exhibition .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005042/en/
“With over 30 years of experience offering state-of-the-art server platforms and server motherboards, TYAN has been recognized by large scale data center customers and server channels,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “Combining the latest innovation from our partners, like Intel and AMD, TYAN customers enable to win the market opportunities precisely with TYAN’s server building block offerings.”
Attendees will experience featured products showcase, webinar sessions and live Q & A during the virtual environment. Heading TYAN’s latest server offerings for the HPC community are Thunder HX FT83-B7119 and Transport HX TS75-B8252 . The FT83-B7119 is built around 2nd Gen Intel Xeon Scalable processors featuring ten double-width PCIe x16 slots for GPUs and 12 hot-swap, tool-less 3.5” drive bays which support up to 4 NVMe U.2 drives in a 4U enclosure. The system is ideal for AI training and inference applications. Powered by 2nd Gen AMD EPYC 7002 series processors, the TS75-B8252 is optimized for virtualization, AI inference and in-memory computing workloads. The 2U server platform features 32 DIMM slots, up to 9 PCIe 4.0 slots, 12 hot-swap, tool-less 3.5” drive bays which support up to 4 NVMe U.2 drives.
Optimized for the challenges facing in Cloud Server Providers, TYAN’s cloud platforms offer outstanding computing density and storage performance in a cost-efficient way. The new 1U Thunder SX GT93-B7106 supports dual socket 2nd Gen Intel Xeon Scalable processors with twelve 3.5” and one 2.5” easy-swap drive bays for software-defined cold storage applications. Featuring 2nd Gen AMD EPYC 7002 series processors, the Transport CX GC68-B8036 accommodates four 3.5” and four 2.5” hot-swap, tool-less drive bays in 1U for both data storage and application cache requirement in data center deployment; the Transport CX TN73-B8037-X4S is a 2U 4-node high-density server platform with support for 16 hot-swap, tool-less 2.5” drive bays supporting both NVMe U.2 and SATA devices. The system is ideal for high IOPs server use cases in data centers.
TYAN offers a full line of storage servers capable of storing massive amounts of data, ranging from 1U high-performance storage server with 12 all-flash drive bays, 2U hybrid storage server to enormous 4U high capacity 100-drive high capacity one. TYAN storage server product line provides a variety of selection for tiered storage requirements in enterprises and data centers.
Please click here for more information and to register.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005042/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom